Resonance Health's FerriScan(R) R2-MRI Receives FDA Marketing Authorization as the First Imaging Companion Diagnostic Device for Exjade(R) in Patients with Non-Transfusion-Dependent Thalassemia

The U.S. Food and Drug Administration announced the authorization of Resonance Health's FerriScan(R) R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia. Exjade(R) (deferasirox) is a drug marketed by Novartis to remove excess iron in patients with genetic blood disorders. In 2005 FerriScan gained FDA marketing clearance for measuring liver iron concentration (LIC).

The FerriScan device is a non-invasive test that helps physicians to select appropriate patients [with NTDT] for Exjade therapy as well as monitor their response to the drug, and discontinue therapy when LIC reaches safe levels.